A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation

Ratna Chatterjee, PhD, MFFP, *Departments of Obstetrics and Gynaecology*; **Susan Wood**, BSc, *Department of Nephrology*; **Hugh H McGarrigle**, PhD, *Departments of Obstetrics and Gynaecology*; **William R Lees**, FRCR, *Department of Nuclear Medicine and Radiology*; **David J Ralph**, FRCS, MSc, *Institute of Urology and Nephrology*; **Guy H Neild**, FRCP, MD, *Institute of Urology and Nephrology, University College Hospitals, London, UK*

Correspondence: Dr Ratna Chatterjee, University College Hospital, Reproductive Medicine Unit, Huntley Street, London WC1E 6AU, UK. Fax: +44 (0) 20 7380 9600. E-mail: rchatterjee1@aol.com

(Accepted 2 February 2004)

Journal of Family Planning and Reproductive Health Care 2004; **30**(2): 88–90

Abstract

Background We undertook a prospective pilot study in a small cohort of patients with renal replacement therapy to determine the cause of erectile dysfunction (ED) and evaluate the role of testosterone replacement therapy and sildenafil.

Methods We investigated 12 patients (eight post-transplant and four on haemodialysis) who presented with ED for hypogonadism and cavernosal insufficiency. We assessed sexual performance before and after treatment by a questionnaire method based on the modified International Index of Erectile Function (IIEF) and National Institutes of Health (NIH) rating. Patients received 250 mg intramuscular monthly injections of testosterone cypionate and 50–100 mg sildenafil orally once or twice weekly for 12 months. Therapeutic response was considered good if the patient could maintain an erection adequate for successful sexual intercourse (NIH criteria) and had a marked improvement in the overall sexual performance (IIEF scoring).

Results Before treatment all patients had severe ED with a poor IIEF score while 11 also had diminished libido. Eleven patients had diminished testicular volume and six had elevated follicle-stimulating hormone levels suggestive of germ cell damage. All patients had a good response to the therapeutic trial of testosterone and sildenafil.

Conclusions Therapy with testosterone and sildenafil may be indicated for those with both cavernosal arterial insufficiency and reproductive hormone abnormalities. Further longer-term data are needed to determine the safety and efficacy of this novel regimen.

multifactorial. The main organic factors are primary^{3,4} or secondary hypogonadism (hypothalamic pituitary dysfunction, hyperprolactinaemia) and penile arterial insufficiency.⁵

Previous attempts at therapy have included intracavernosal injections of vasoactive agents, such as alprostadil, papaverine^{6,7} or penile prosthesis.⁸ All are associated with poor results due to poor tolerance, prosthetic infection and cylinder leak.⁹ The use of the oral agent, type 5 phosphodiesterase inhibitor, sildenafil citrate, has been used successfully in patients on renal dialysis¹⁰ and after renal transplantation.¹¹

Vasoactive drugs, however, may fail to correct sexual dysfunction if libido is also affected. Patients with renal transplant and dialysis may have testosterone deficiency, which can cause reduced libido.^{2,3} Reports are conflicting on the value of testosterone in renal patients, especially as testosterone levels may return to normal in some patients after transplantation.² However, patients may have normal testosterone levels with diminished Leydig cell reserve, which can contribute to symptoms of androgen insufficiency including diminished libido.¹² Other advantages of testosterone include its potential cavernosal vasodilator activity.¹³ A meta-analysis of studies confirms the beneficial effects of testosterone supplementation in patients with ED.¹⁴ A similar improvement is expected in patients with renal replacement, especially if they have hypogonadism.

We undertook a pilot study in a small cohort of patients with renal replacement or on dialysis to determine the cause of ED and to institute a trial of sildenafil and testosterone therapy, as this treatment had been successful in a group of patients with haematological malignancies.¹⁵

Methods

We prospectively studied 12 patients over the period 1997–2001, who presented with ED, either after renal transplantation (n = 8) or while on haemodialysis (n = 4). Clinical data are given in Table 1. All patients older than 50 years and those with a history of cardiovascular disease were screened for potential contraindications before treatment.

We assessed testicular function by measuring testicular volume (ultrasound and orchidometer).¹⁶ Hyperplasia or adenoma was excluded by prostatic ultrasound. All patients had an endocrine profile (Table 2). All hormones were assayed by standard radio-immunoassay using double antibody techniques.¹⁷

Key message points

- Patients with erectile dysfunction (ED) who were receiving dialysis or had renal transplantation were shown to have cavernosal arteriogenic insufficiency and abnormal reproductive hormone profiles.
- Investigations to determine the aetiology of ED may help to guide therapeutic options.
- Therapy with sildenafil and testosterone should be considered in patients who have cavernosal arteriogenic insufficiency and abnormal reproductive hormone profiles. Patients receiving immunosuppressant drugs require monitoring as they are at higher risk of the carcinogenic and other side effects of testosterone.

Introduction

Erectile dysfunction (ED) affects 40–100% of men on renal replacement therapy, including dialysis and transplantation.^{1,2} The aetiology is usually

Table 1 Clinical data

Patient	Age (years)	Primary renal diagnosis	Other characteristics	RRT	Sexual dysfunction			
					Duration (years)	ED grade	Libido	Ejaculation
1	40	IDDM	Retinopathy, porphyria, peripheral vascular disease, osteoporosis	CRT	4	I	Diminished	Normal
2	29	Prune belly syndrome	Left orchidectomy, IDDM, Peyronie's disease	LRT	2	I	Diminished	Aejaculation
3	44	Amyloid	Bilateral hip and knee arthroplasty, osteoporosis	HD	1	I	Diminished	Aejaculation
4	56	Polycystic kidney	Mild ischaemic heart disease, Still's disease	CRT	3	I	Diminished	Normal
5	39	Prune belly syndrome	Gout, duodenal ulcer, morbid obesity, orchidopexy	CRT	4	I	Diminished	Aejaculation
6	43	Hypertension	Hyperaldosteronism, adrenalectomy	CRT*	1	I	Diminished	Normal
7	27	Obstructive uropathy	Cytomegalovirus, chronic active hepatitis, positive hepatitis C	HD*	2	I	Diminished	Normal
8	48	IDDM	Retinopathy, neuropathy	CRT	1	I	Diminished	Normal
9	51	Chronic glomerulonephritis	Mild ischaemic heart disease	CRT	2	I	Diminished	Normal
10	49	Obstructive uropathy		HD	1	I	Diminished	Normal
11	33	IDDM	Retinopathy, neuropathy	HD	1	I	Normal	Painful
12	45	Chronic glomerulonephritis		CRT	2	II	Diminished	Premature

CRT, cadaveric renal transplant; CRT*, second transplant; ED, erectile dysfunction; HD, haemodialysis; HD*, failed transplant; IDDM, insulin-dependent diabetes mellitus; LRT, live related transplant; RRT, renal replacement therapy.

Colour flow Doppler was undertaken to assess haemodynamic function of the penis after injection of a vasoactive agent to induce an erection.¹⁸ The response to intracavernosal injection was graded as: 0 = nil erection; I = tumescence only; II = partial and III = full rigidity according to our previously published data.¹⁶

All patients had a therapeutic trial of 12 months of 250 mg intramuscular monthly injections of testosterone cypionate and 50–100 mg sildenafil orally, once or twice weekly. Therapeutic response was considered good if the patient could maintain an erection adequate for successful sexual intercourse measured by the National Institute of Health (NIH) rating¹⁹ and International Index of Erectile Function (IIEF) scores.²⁰ The regime was in accordance with our previously published data.¹⁵ All patients gave written informed consent to participate in this study as approved by the local research ethics

committee of the University College London Hospitals Trust.

Results

Table 1 shows the clinical features and Table 2 the baseline endocrine and investigative data of the patients at the onset of the study. All transplant patients had renal transplantation at least 12 months before and had stable renal function for 6 months before and during the study period. No patients had contraindications to therapy. Only one patient (Patient 10) did not have diminished testicular volume and six had elevated follicle-stimulating hormone levels. While only two patients had low testosterone levels, others had a variety of reproductive hormone abnormalities (Table 2). All patients responded to treatment (Table 3). There were no adverse effects or deterioration of renal function and compliance was excellent.

Table 2 Endocrine and investigative data at the onset of the study

Patient	Testicular volume (ml)		Mean penile Doppler flow (PSV cm/second)	FSH (IU/l)	LH (IU/l)	Prolactin (mIU/l)	Testosterone (nmol/l)	Free testosterone (%)	T/LH ratio	SHBG (nmol/l)	Androstenedione (nmol/l)	DHEAS (mmol/l)	E ₂ (pmol)
	Right	Left											
1	12.0	12.0	18	29.7	3.1	900	16.1	1.4	5.20	47.0	4.5	16.0	150
2	Absent	10.0	7.0	38.8	16.0	1000	9.4	1.2	0.58	28.0	12.0	14.0	140
3	3.0	3.0	25.0	19.4	12.4	100	10.8	1.8	0.88	23.0	6.0	8.0	40
4	8.0	8.0	15.0	12.2	10.0	120	12.8	1.8	1.28	32.2	12.0	18.0	60
5	5.5	3.8	6.5	10.6	16.8	90	11.9	1.4	0.71	20.0	10.0	14.0	70
6	11.0	12.0	20.0	11.0	2.0	200	11.0	1.9	5.5	20.0	12.0	18.0	40
7	14.0	14.0	18.0	5.5	5.6	800	25.8	1.8	4.61	30.0	20.0	12.0	120
8	8.0	10.0	15.0	16.4	10.8	340	8.0	1.4	0.74	30.0	20.0	18.0	30
9	8.0	8.0	20.0	12.2	18.2	300	7.9	1.8	0.43	28.0	18.0	12.0	60
10	17.0	16.0	30.0	8.8	7.4	600	27.4	1.6	3.70	31.0	10.3	10.0	80
11	8.0	8.0	18.0	18.0	12.0	400	9.8	1.2	0.82	30.0	10.0	18.0	100
12	10.0	10.0	40	16.0	6.2	450	14.0	2.1	2.26	14.0	4.7	19.0	90
Range	3–17	3–16	6.5–40	1–38.8	2–18.2	120–1000	13.75	1.2–2.1	0.4–5.5	14–47	4.5–20	8–19	30–150
Median	8.0	10.0	18.0	14.1	10.4	370.0	11.45	1.7	1.1	29	11.15	15.0	75.0
Normal values	15–25		>30	2–12	2–12	0–620	9–33	1.34 to >2.4	2.75–4.5	10–48	4–10	2–12	30–300

DHEAS, dehydroepiandrosterone sulphate; E₂, oestradiol; FSH, follicle-stimulating hormone; LH, luteinising hormone; PSV, peak systolic velocity; SHBG, sex hormone-binding globulin; T, testosterone.

Table 3 Endocrine and sexual function pretreatment vs post-treatment

Patient	IIEF score			NIH rating		
	0/12	6/12	9/12	0/12	6/12	9/12
1	23	65	66	P	S	S
2	16	69	65	P	S	S
3	16	66	64	P	S	S
4	17	66	68	P	S	S
5	20	65	66	P	S	S
6	22	66	68	P	S	S
7	16	65	66	P	S	S
8	18	64	66	P	S	S
9	20	65	68	P	S	S
10	23	65	65	P	S	S
11	24	64	66	P	S	S
12	25	60	62	P	S	S
Median	20	65	66			
Range	16–25	60–69	62–68			

IIEF, International Index of Erectile Function; NIH, National Institutes of Health; P, poor; S, satisfactory.

Discussion

We found reproductive hormonal abnormalities and cavernosal insufficiency in renal patients presenting with ED. We used combination therapy with testosterone and sildenafil successfully in these patients. We found a similar favourable outcome for erectile performance in cancer patients using the same therapeutic regimen.¹⁵ The main advantage of sildenafil is that it effectively treats ED, whatever the cause. This is relevant in renal diseases where multiple organic and psychogenic disorders are present. Although cardiac, retinal and vasomotor symptoms have been described with sildenafil, the adverse effects are infrequent and generally mild.^{21,22}

Sildenafil monotherapy is likely to be less effective in patients who have diminished libido due to Leydig cell insufficiency.³ Since sildenafil only works on a sexually stimulated penis²³ addition of testosterone can be synergistic. Testosterone can improve symptoms such as energy, drive and generalised symptoms of depression and fatigue. Some trials have shown the efficacy of testosterone in ED patients.^{13,24,25} Dual therapy with testosterone and sildenafil may be beneficial in this group of patients. We recommend selection of patients by excluding those with contraindications to either medication.

The mixed aetiology of ED in these patients suggests that similar patients with ED should have investigations to determine the aetiology of the condition. Therapy with testosterone and sildenafil may be indicated for those with both cavernosal arterial insufficiency and reproductive hormone abnormalities. We recommend long-term follow-up of these patients for cardiovascular effects, in addition to prostate specific antigen assays and prostatic ultrasound,²⁶ as patients taking immunosuppressant drugs are at higher carcinogenic risk on testosterone. A prospective study using the above regime in a large sample size of patients on renal replacement therapy is currently underway.

Acknowledgements

The authors acknowledge members of the staff of the Departments of Reproductive Medicine, Nuclear Medicine and Radiology, Urology, and the Antrim and Mary Rankin Wards for their support in conducting the study.

Statements on funding and competing interests

Funding. None identified.
Competing interests. None identified.

References

1 Lawrence IG, Price DE, Howlett TA, et al. Correcting impotence in the male dialysis patient: testosterone replacement and vacuum tumescence. *Am J Kidney Dis* 1998; **2**: 313–319.

2 Carsson CC, Patel MP. The epidemiology, anatomy, physiology, and treatment of erectile dysfunction in chronic renal failure patients. *Adv Ren Replace Ther* 1999; **6**: 296–309.

3 Burgos FJ, Pascual J, Gomez V, et al. Effect of kidney transplantation and cyclosporine treatment on male sexual performance and hormonal profile: a prospective study. *Transplant Proc* 1997; **29**: 227.

4 Kaufman JM, Hatzichristou DG, Mulhall JP, et al. Impotence and chronic renal failure: a study of the haemodynamic pathophysiology. *J Urol* 1994; **151**: 612–618.

5 Coppola A, Cuomo G. Pituitary–testicular evaluation in patients with chronic renal insufficiency in haemodialysis treatment. *Minerva Med* 1999; **81**: 461.

6 Rodriguez Antolin A, Morales JM, Andres A, et al. Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs. *Transplant Proc* 1992; **24**: 105–106.

7 Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. *J Urol* 1998; **159**: 1927–1930.

8 Ahuja SK, Krane NK, Hellstrom WJ. Penile prosthesis in the management of impotence in patients with end-stage renal disease. *J La State Med Soc* 1998; **150**: 32–34.

9 Rowe SJ, Montague DK, Steinmuller DR, et al. Treatment of organic impotence with penile prosthesis in renal transplant patients. *Urology* 1993; **41**: 16–20.

10 Seibel I, Poli De Figueiredo CE, et al. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. *J Am Soc Nephrol* 2002; **13**: 2770–2775.

11 Barrou B, Cuzin B, Malavaud B, et al. Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. *Nephrol Dial Transplant* 2003; **18**: 411–417.

12 Chatterjee R, Kottaridis PD, HH McGarrigle, et al. Patterns of Leydig cell insufficiency in adult males, following bone marrow transplantation for haematological malignancies. *Bone Marrow Transplant* 2001; **28**: 497–502.

13 Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilatation in men with erectile dysfunction. *Clin Endocrinol (Oxf)* 2000; **53**: 517–522.

14 Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. *J Urol* 2000; **164**: 371–375.

15 Chatterjee R, Kottaridis PD, McGarrigle HH, et al. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. *Bone Marrow Transplant* 2002; **29**: 607–610.

16 Chatterjee R, Kottaridis P D, Lees WR, et al. Cavernosal arterial insufficiency and erectile dysfunction in recipients of high-dose chemotherapy and total body irradiation for multiple myeloma. *Lancet* 2000; **355**(9212):1335–1336.

17 Chatterjee R, Mills W, Katz M, et al. Germ cell failure and Leydig cell insufficiency in post-pubertal males after BEAM for lymphoma. *Bone Marrow Transplant* 1994; **13**: 519–522.

18 Patel U, Amin Z, Friedman E, et al. Colour Doppler imaging in 220 men: the role of repeated sampling, velocity asymmetry and vascular anomalies. *Clin Radiol* 1993; **48**: 18–24.

19 National Institutes of Health Consensus Statement. *Impotence* 1992; **7**: 101–131.

20 Rosen RC. The International Index of Erectile Function (IIEF): a multicentric scale for assessment of erectile dysfunction. *Urology* 1997; **49**: 822–830.

21 Osterloh JH, Collins M, Wicker P, et al. Sildenafil citrate (Viagra): overall safety profile in 18 double blind, placebo controlled clinical trials. *Int J Clin Pract Suppl* 1999; **102**: 3–5.

22 Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil treatment of erectile dysfunction. *N Engl J Med* 1998; **338**: 1397–1404.

23 Lue TF. Erectile dysfunction. *N Engl J Med* 2000; **342**: 1802–1813.

24 Levy A, Crowley T, Gingell C. Non-surgical management of erectile dysfunction. *Clin Endocrinol (Oxf)* 2000; **52**: 253–260.

25 Nehra A. Treatment of endocrinologic male sexual dysfunction. *Mayo Clin Proc* 2000; **75**(Suppl.): S40–S45

26 Hafez B. Recent advances in clinical/molecular andrology. *Arch Androl* 1998; **40**:187–210.

Visit the Faculty website at: www.ffprhc.org.uk